Paul W.A. Janssen

A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI

Daniel M.F. Claassens, Gerrit J.A. Vos, Thomas O. Bergmeijer et al. · New England Journal of Medicine · 2019 · 597 citations · Full text

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

Stefanie Schüpke, Robert A. Byrne, Jurriën M. ten Berg et al. · European Heart Journal · 2015 · 423 citations · Full text

CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study

Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper et al. · American Heart Journal · 2014 · 81 citations

Thrombosis, Percutaneous Coronary Intervention, Antiplatelet Therapy +12

Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG)

Laura M. Willemsen, Paul W.A. Janssen, Joyce Peper et al. · Circulation · 2020 · 63 citations · Full text

Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial

Willem J.M. Dewilde, Paul W.A. Janssen, Johannes C. Kelder et al. · EuroIntervention · 2015 · 50 citations